What do systematic reviews say?

First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors vs first‐line ciclosporin and/or antithymocyte or antilymphocyte globulin

First‐line allogeneic hematopoietic stem cell transplantation of… showed no clear difference in overall mortality compared with first‐line ciclosporin and/or antithymocyte or antilymphocyte globulin (low certainty).

• First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors compared with first‐line… 2013 · Cochrane Headline outcomes only
  HR 0.95 [0.45, 1.91]
  3 studies · 203 participants
  Low

First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors vs first‐line ciclosporin and/or antithymocyte or antilymphocyte globulin

• First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors compared with first‐line… 2013 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 54 participants
  Very low

First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors vs first‐line ciclosporin and/or antithymocyte or antilymphocyte globulin

• First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors compared with first‐line… 2013 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors vs first‐line ciclosporin and/or antithymocyte or antilymphocyte globulin

• First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors compared with first‐line… 2013 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 54 participants
  Very low

First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors vs first‐line ciclosporin and/or antithymocyte or antilymphocyte globulin

• First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors compared with first‐line… 2013 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 35 participants
  Very low

First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors vs first‐line ciclosporin and/or antithymocyte or antilymphocyte globulin

• First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors compared with first‐line… 2013 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 52 participants
  Very low

First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors vs first‐line ciclosporin and/or antithymocyte or antilymphocyte globulin

First‐line allogeneic hematopoietic stem cell transplantation of… showed no clear difference in secondary clonal disease or malignancies compared with first‐line ciclosporin and/or antithymocyte or antilymphocyte globulin (low certainty).

• First‐line allogeneic hematopoietic stem cell transplantation of HLA‐matched sibling donors compared with first‐line… 2013 · Cochrane Headline outcomes only
  Peto OR 0.54 [0.07, 4]
  2 studies · 170 participants
  Low

Plerixafor vs placebo

Plerixafor leads to higher successful stem cell collection compared with placebo (high certainty).

• Additional plerixafor to granulocyte colony‐stimulating factors for haematopoietic stem cell mobilisation for… 2015 · Cochrane Headline outcomes only
  RR 2.42 [1.98, 2.96]
  2 studies · 600 participants
  High

Plerixafor vs placebo

Plerixafor showed no clear difference in adverse events (during stem cell mobilisation and collection) compared with placebo (high certainty).

• Additional plerixafor to granulocyte colony‐stimulating factors for haematopoietic stem cell mobilisation for… 2015 · Cochrane Headline outcomes only
  RR 1.02 [0.99, 1.06]
  2 studies · 593 participants
  High

Intervention not reported

The intervention showed no clear difference in overall survival (at 36 months) (moderate certainty).

• Polyclonal anti‐thymocyte globulins for the prophylaxis of graft‐versus‐host disease after allogeneic stem cell or… 2023 · Cochrane Headline outcomes only
  HR 0.93 [0.77, 1.13]
  9 studies · 1249 participants
  Moderate

Intervention not reported

The intervention leads to lower acute GVHD II to IV (90 days) (high certainty).

• Polyclonal anti‐thymocyte globulins for the prophylaxis of graft‐versus‐host disease after allogeneic stem cell or… 2023 · Cochrane Headline outcomes only
  RR 0.68 [0.6, 0.79]
  10 studies · 1413 participants
  High

Intervention not reported

The intervention leads to lower overall Chronic GVHD (up to 36 months) (high certainty).

• Polyclonal anti‐thymocyte globulins for the prophylaxis of graft‐versus‐host disease after allogeneic stem cell or… 2023 · Cochrane Headline outcomes only
  RR 0.53 [0.45, 0.61]
  8 studies · 1273 participants
  High

Intervention not reported

The intervention showed no clear difference in incidence of relapse (up to 36 months) (moderate certainty).

• Polyclonal anti‐thymocyte globulins for the prophylaxis of graft‐versus‐host disease after allogeneic stem cell or… 2023 · Cochrane Headline outcomes only
  RR 1.21 [0.99, 1.49]
  8 studies · 1315 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in non‐relapse mortality (at 36 months) (moderate certainty).

• Polyclonal anti‐thymocyte globulins for the prophylaxis of graft‐versus‐host disease after allogeneic stem cell or… 2023 · Cochrane Headline outcomes only
  HR 0.86 [0.67, 1.11]
  9 studies · 1370 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in graft failure (during study) (low certainty).

• Polyclonal anti‐thymocyte globulins for the prophylaxis of graft‐versus‐host disease after allogeneic stem cell or… 2023 · Cochrane Headline outcomes only
  RR 1.55 [0.54, 4.44]
  8 studies · 1240 participants
  Low

Intervention not reported

• Polyclonal anti‐thymocyte globulins for the prophylaxis of graft‐versus‐host disease after allogeneic stem cell or… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 543 participants
  Moderate

Thrombopoietin mimetics vs placebo or usual care

It is very uncertain whether thrombopoietin mimetics changes number of participants with at least 1 bleeding episode compared with placebo or standard care (very low certainty).

• Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies… 2016 · Cochrane Headline outcomes only
  OR 0.4 [0.1, 1.62]
  1 study · 120 participants
  Very low

Intervention not reported

It is very uncertain whether the intervention changes number of participants with severe or life‐threatening bleeding (very low certainty).

• Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies… 2016 · Cochrane Headline outcomes only
  OR 4 [0.56, 28.4]
  1 study · 18 participants
  Very low

Intervention not reported

The review found no eligible studies for this question.

• Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies… 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The review found no eligible studies for this question.

• Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies… 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found